Moderna Inc (MRNA) concluded trading on Tuesday at a closing price of $41.58, with 7.4 million shares of worth about $307.68 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -64.48% during that period and on December 31, 2024 the price saw a gain of about 5.59%. Currently the company’s common shares owned by public are about 385.00M shares, out of which, 343.19M shares are available for trading.
Stock saw a price change of 5.03% in past 5 days and over the past one month there was a price change of -3.44%. Year-to-date (YTD), MRNA shares are showing a performance of -58.19% which decreased to -58.19% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $35.80 but also hit the highest price of $170.47 during that period. The average intraday trading volume for Moderna Inc shares is 7.53 million. The stock is currently trading 0.49% above its 20-day simple moving average (SMA20), while that difference is down -7.10% for SMA50 and it goes to -53.45% lower than SMA200.
Moderna Inc (NASDAQ: MRNA) currently have 385.00M outstanding shares and institutions hold larger chunk of about 67.52% of that.
The stock has a current market capitalization of $16.89B and its 3Y-monthly beta is at 1.60. It has posted earnings per share of -$5.82 in the same period. It has Quick Ratio of 4.20 while making debt-to-equity ratio of 0.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MRNA, volatility over the week remained 4.40% while standing at 5.75% over the month.
Analysts are in expectations that Moderna Inc (MRNA) stock would likely to be making an EPS of -2.57 in the current quarter, while forecast for next quarter EPS is -3.13 and it is -8.68 for next year. For the current quarter EPS, analysts have given the company a lowest target -3.34 which is -1.85 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 0.55 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 24.34% while it is estimated to increase by 4.16% in next year.
Coverage by BofA Securities stated Moderna Inc (MRNA) stock as an Underperform in their note to investors on December 10, 2024, suggesting a price target of $41 for the stock. On November 19, 2024, Berenberg Initiated their recommendations, while on November 18, 2024, HSBC Securities Upgrade their ratings for the stock with a price target of $58. Stock get an Underperform rating from Wolfe Research on November 15, 2024.
